Table 2.
Studies of the gut microbiome in NAFLD patients
| Study | Country | Samples | Groups | Method | NAFLD-enriched Taxa | Controls-enriched Taxa |
|---|---|---|---|---|---|---|
| Bacteria | ||||||
| Zhu et al.137 | USA | Stool | NASH (22) vs. obese (25) vs. HC (16) | 16S rRNA | Proteobacteria, Enterobacteriaceae, Escherichia | / |
| Mouzaki et al.138 | Canada | Stool | Simple steatosis (11) vs. NASH (22) vs. HC (17) | PCR | Clostridium coccoides | Bacteroidetes |
| Alferink et al.136 | Netherlands | Stool | No steatosis (883) vs. steatosis (472) | 16S rRNA | Ruminococcus gauvreauiigroup, Ruminococcus gnavusgroup | Coprococcus3 |
| Loomba et al.139 | USA | Stool | NAFLD (72) vs. advanced fibrosis (14) | Metagenomics | Proteobacteria, Escherichia coli | Fimicutes |
| Viruses | ||||||
| Lang et al.140 | Germany | Stool | NAFLD (73) vs. PBC (13) vs. HC (9) | 16S rRNA + Metagenomics | Escherichia phage, Enterobacteria phage, Lactobacillus phage | / |
NAS NAFLD activity score